Analysts think BMRN stock price could increase by 52%
Feb 02, 2025, 12:25 PM
12.21%
What does BMRN do
BioMarin Pharmaceutical, headquartered in San Rafael, California, develops therapies for serious rare diseases and employs 3,401 people. Its products include Vimizim, Roctavian, and Voxzogo for various medical conditions.
29 analysts think BMRN stock price will increase by 52.25%. The current median analyst target is $96.39 compared to a current stock price of $63.31. The lowest analysts target is $65.65 and the highest analyst target is $133.35.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
